Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood tests may reveal who will get severe COVID-19

NCT ID NCT04668170

Knowledge-focused Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study analyzed blood samples from 304 COVID-19 patients in France to find early immune markers that predict whether someone will become severely ill. Researchers looked at T-cells and inflammatory chemicals in the blood to understand why some people worsen while others recover. The goal is to help doctors tailor treatments earlier based on a patient's immune response.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify early which COVID-19 patients are at risk of severe illness, allowing for quicker, more personalized treatment.
What could go wrong
This is an observational study, not a treatment trial. The findings may not lead to immediate clinical changes and need further validation in larger, diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

304 people

The number who actually took part.

Started

May 2020

Finished

May 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients hospitalized or healthy workers for COVID-19

Ages

18 to 110 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For COVID-19 hospitalized patients * Polymerase chain reaction (PCR) proven SARS-CoV-2 infection * Participation to Toulouse clinical cohort * Having signed consent for inclusion in the Toulouse biobanks For COVID-19 healthcare workers attending dedicated clinics * PCR proven SARS-CoV-2 infection * Having signed consent for inclusion in the Toulouse biobanks Exclusion Criteria: * Pregnancy or breastfeeding * Participation in another interventional clinical study involving exploratory treatment or blood sampling.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

  • University Hospital Bordeaux

    Bordeau, 33000, France

  • University Hospital Toulouse

    Toulouse, 31059, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.